AVEO Oncology announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate Fotivda — AVEO's newly approved drug — in combination with BMS's Opdivo, in patients with advanced relapsed or refractory renal cell carcinoma (RCC) following prior immunotherapy exposure.
Boston-based AVEO received the U.S. FDA nod for Fotivda on March 10, for the treatment of adult patients with relapsed or refractory advanced RCC following two or more prior systemic therapies.
Now, they are launching a trial to test the new drug with BMS’ checkpoint therapy in a phase 3 trial, hoping that combining the kinase inhibitor and an immunotherapy could lead to a better outcome for patients.
The randomized, open-label, controlled TiNivo-2 Phase 3 trial is expected to enroll approximately 326 patients with advanced RCC who have progressed following prior immunotherapy treatment.
Read the press release